Literature DB >> 22562113

Familial predisposition to alcoholic liver disease: a case-control study.

Ala K Ali1, Jayne S Jones, Martin P Bradley, Neeraj Bhala, Arifur Rahman, Robert J Peck, Dawn M Teare, Dermot Gleeson.   

Abstract

OBJECTIVES: The variable susceptibility to alcoholic liver disease (ALD) may be genetic in origin, but clear candidate genes have not yet emerged. This study aimed to assess familial clustering of ALD using a case-control strategy.
METHODS: We recruited two cohorts of heavy drinkers (>60 U/week for men or >40 U/week for women): 291 individuals with decompensated ALD (Child's grade B or C) and 208 controls with similar alcohol consumption but no evidence of liver disease. Data were collected, through a questionnaire and a follow-up telephone call, on drinking behaviour and the presence of liver disease in parents and siblings of cases and controls. The results in the relatives of cases were compared with those in the relatives of the controls.
RESULTS: The odds ratio (OR) of heavy drinking in the relatives of the cases compared with the controls was 0.91 [95% confidence interval (CI), 0.73-1.1]. OR in the relatives of the cases versus the controls was 1.27 for definite ALD (95% CI, 0.63-2.6), 1.09 for all ALD (95% CI, 0.58-2.0) and 1.0 for all liver diseases (95% CI, 0.60-1.7). Multiple subgroup analyses yielded similar OR values, not exceeding 1.5.
CONCLUSION: These data do not suggest a strong familial predisposition to the development of ALD and rather suggest that the main cofactors are environmental.

Entities:  

Mesh:

Year:  2012        PMID: 22562113     DOI: 10.1097/MEG.0b013e328353a367

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  1 in total

1.  Prognostic Significance of the Systemic Inflammatory and Immune Balance in Alcoholic Liver Disease with a Focus on Gender-Related Differences.

Authors:  Beata Kasztelan-Szczerbińska; Agata Surdacka; Krzysztof Celiński; Jacek Roliński; Agnieszka Zwolak; Sławomir Miącz; Mariusz Szczerbiński
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.